J Kenneth Glass - Net Worth and Insider Trading

J Kenneth Glass Net Worth

The estimated net worth of J Kenneth Glass is at least $1 Million dollars as of 2024-04-19. J Kenneth Glass is the Director of FedEx Corp and owns about 5,000 shares of FedEx Corp (FDX) stock worth over $1 Million. J Kenneth Glass is also the Director of Oncternal Therapeutics Inc and owns about 178 shares of Oncternal Therapeutics Inc (ONCT) stock worth over $1,531. Details can be seen in J Kenneth Glass's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that J Kenneth Glass has not made any transactions after 2016-03-01 and currently still holds the listed stock(s).

Transaction Summary of J Kenneth Glass

To

J Kenneth Glass Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, J Kenneth Glass owns 3 companies in total, including Oncternal Therapeutics Inc (ONCT) , First Horizon Corp (FHN) , and FedEx Corp (FDX) .

Click here to see the complete history of J Kenneth Glass’s form 4 insider trades.

Insider Ownership Summary of J Kenneth Glass

Ticker Comapny Transaction Date Type of Owner
ONCT Oncternal Therapeutics Inc 2016-03-01 director
FHN First Horizon Corp 2003-07-01 director & President & CEO
FDX FedEx Corp 2003-12-31 director

J Kenneth Glass Latest Holdings Summary

J Kenneth Glass currently owns a total of 2 stocks. Among these stocks, J Kenneth Glass owns 5,000 shares of FedEx Corp (FDX) as of December 31, 2003, with a value of $1 Million and a weighting of 99.88%. J Kenneth Glass also owns 178 shares of Oncternal Therapeutics Inc (ONCT) as of March 1, 2016, with a value of $1,531 and a weighting of 0.12%.

Latest Holdings of J Kenneth Glass

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
FDX FedEx Corp 2003-12-31 5,000 263.37 1,316,850
ONCT Oncternal Therapeutics Inc 2016-03-01 178 8.60 1,531

Holding Weightings of J Kenneth Glass


J Kenneth Glass Form 4 Trading Tracker

According to the SEC Form 4 filings, J Kenneth Glass has made a total of 0 transactions in FedEx Corp (FDX) over the past 5 years. The most-recent trade in FedEx Corp is the acquisition of 5,000 shares on December 31, 2003, which cost J Kenneth Glass around $341,700.

According to the SEC Form 4 filings, J Kenneth Glass has made a total of 0 transactions in Oncternal Therapeutics Inc (ONCT) over the past 5 years. The most-recent trade in Oncternal Therapeutics Inc is the acquisition of 31 shares on March 1, 2016, which cost J Kenneth Glass around $26,400.

Insider Trading History of J Kenneth Glass

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

J Kenneth Glass Trading Performance

GuruFocus tracks the stock performance after each of J Kenneth Glass's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by J Kenneth Glass is 15.41%. GuruFocus also compares J Kenneth Glass's trading performance to market benchmark return within the same time period. The performance of stocks bought by J Kenneth Glass within 3 months outperforms 9 times out of 17 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how J Kenneth Glass's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of J Kenneth Glass

Average Return

-10.45%

Average return per transaction

Outperforming Transactions

25%

4 out of 16 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 10.4 15.41 8.11 -10.45 -4.27 -8.57
Relative Return to S&P 500(%) 12.35 15.05 5 -20.66 -15.85 -17.42

J Kenneth Glass Ownership Network

Ownership Network List of J Kenneth Glass

No Data

Ownership Network Relation of J Kenneth Glass


J Kenneth Glass Owned Company Details

What does Oncternal Therapeutics Inc do?

Who are the key executives at Oncternal Therapeutics Inc?

J Kenneth Glass is the director of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .

Oncternal Therapeutics Inc (ONCT) Insider Trades Summary

Over the past 18 months, J Kenneth Glass made no insider transaction in Oncternal Therapeutics Inc (ONCT). Other recent insider transactions involving Oncternal Therapeutics Inc (ONCT) include a net purchase of 9,020 shares made by Robert James Wills , a net purchase of 150,000 shares made by James B Breitmeyer , and a net purchase of 30,000 shares made by Richard G Vincent .

In summary, during the past 3 months, insiders sold 980 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 10,980 shares, with a net purchase of 10,000 shares. During the past 18 months, 980 shares of Oncternal Therapeutics Inc (ONCT) were sold and 23,880 shares were bought by its insiders, resulting in a net purchase of 22,900 shares.

Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Oncternal Therapeutics Inc Insider Transactions

No Available Data

J Kenneth Glass Mailing Address

Above is the net worth, insider trading, and ownership report for J Kenneth Glass. You might contact J Kenneth Glass via mailing address: 175 Toyota Plaza, 7th Floor, Memphis Tn 38103.

Discussions on J Kenneth Glass

No discussions yet.